Three-dimensional (3D) cell culture technology is one of the fastest growing experimental approaches in the life sciences. The 3D cell culture market was valued at $438.1 million in 2013 and is expected to grow to about $2.2 billion in 2019 (BCC Research Biotechnology Report). The technology has progressed to the extent that cell-based in vitro assays are now being used throughout the drug discovery and development chain. A major challenge, however, is the translation of in vitro assays to the corresponding in vivo outcomes. Physiological relevance is a key parameter to improve the predictive power of cell-based assays, and the more we can reflect tissue architecture, composition and function, the more predicitve in vitro assays will become. For this reason 3D cell culture needs to enter its next phase of development: Technology maturation, optimization of assays, protocols and kits, and compatibility with automated lab equipment. The goal is the implementation of easy-to-handle biomimetic tissue constructs that simulate the in vivo condition in a reproducible and reliable way.
22 October, 2015
Kompetenzentrum TEDD, Institut für Chemie und Biologische Chemie, ZHAW Life Science and Facility Management